{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T15:00:31Z","timestamp":1778857231457,"version":"3.51.4"},"reference-count":26,"publisher":"Wiley","issue":"8","license":[{"start":{"date-parts":[[2021,8,7]],"date-time":"2021-08-07T00:00:00Z","timestamp":1628294400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["headachejournal.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Headache"],"published-print":{"date-parts":[[2021,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>We conducted a randomized trial among emergency department patients with migraine to determine the relative impact on migraine\u2010associated symptoms of hydromorphone, an opioid, versus prochlorperazine, an antidopaminergic antiemetic.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      This was a post hoc analysis of data from a double\u2010blind study registered at\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"http:\/\/clinicaltrials.gov\">http:\/\/clinicaltrials.gov<\/jats:ext-link>\n                      (NCT02389829). Patients who met International Classification of Headache Disorders, 3rd edition criteria for migraine without aura or for probable migraine without aura were eligible for participation. Participants received either hydromorphone 1\u00a0mg IV or prochlorperazine 10\u00a0mg IV plus diphenhydramine 25\u00a0mg IV and could receive a second dose of the same medication 1\u00a0h later if needed. The outcomes were sustained relief of nausea, photophobia, and phonophobia.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      A total of 127 patients were enrolled, of whom 63 received prochlorperazine and 64 received hydromorphone. Of 49 patients in the prochlorperazine arm who reported nausea at baseline, 34 (69.4%) reported complete resolution without relapse versus 15\/49 (30.6%) in the hydromorphone arm (absolute risk reduction [ARR]\u00a0=\u00a038.8%, 95% CI: 20.5%\u201357.0%,\n                      <jats:italic>p<\/jats:italic>\n                      \u00a0&lt;\u00a00.001). Of 55 patients in the prochlorperazine arm who reported photophobia at baseline, 23 (41.8%) reported complete resolution without relapse versus 13\/62 (20.9%) patients treated with hydromorphone (ARR\u00a0=\u00a020.8%, 95% CI: 4.3%\u201337.3%,\n                      <jats:italic>p<\/jats:italic>\n                      \u00a0=\u00a00.014). Of 56 patients in the prochlorperazine arm who reported phonophobia at baseline, 25 (44.6%) reported complete resolution without relapse versus 16\/59 (27.1%) in the hydromorphone arm (ARR\u00a0=\u00a017.5%, 95% CI: 0.3%\u201334.8%,\n                      <jats:italic>p<\/jats:italic>\n                      \u00a0=\u00a00.049). For adverse events, three patients in the prochlorperazine arm reported anxiety or restlessness, and nine patients in the hydromorphone arm reported dizziness or weakness.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Prochlorperazine plus diphenhydramine is more efficacious than hydromorphone for the treatment of migraine\u2010associated symptoms.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/head.14185","type":"journal-article","created":{"date-parts":[[2021,8,7]],"date-time":"2021-08-07T11:09:01Z","timestamp":1628334541000},"page":"1227-1233","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["A randomized study of IV prochlorperazine plus diphenhydramine versus IV hydromorphone for migraine\u2010associated symptoms: A post hoc analysis"],"prefix":"10.1111","volume":"61","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3436-2846","authenticated-orcid":false,"given":"Fred","family":"Cohen","sequence":"first","affiliation":[{"name":"Department of Medicine Montefiore Medical Center Albert Einstein College of Medicine Bronx NY USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benjamin W.","family":"Friedman","sequence":"additional","affiliation":[{"name":"Department of Emergency Medicine Montefiore Medical Center Albert Einstein College of Medicine Bronx NY USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2021,8,7]]},"reference":[{"key":"e_1_2_12_2_1","doi-asserted-by":"publisher","DOI":"10.1177\/0333102414539055"},{"key":"e_1_2_12_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/head.12233"},{"key":"e_1_2_12_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/head.12835"},{"key":"e_1_2_12_5_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000004642"},{"key":"e_1_2_12_6_1","doi-asserted-by":"publisher","DOI":"10.1177\/0333102417738202"},{"key":"e_1_2_12_7_1","doi-asserted-by":"publisher","DOI":"10.1067\/mem.2001.113032"},{"key":"e_1_2_12_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annemergmed.2007.09.027"},{"issue":"1","key":"e_1_2_12_9_1","first-page":"S95","article-title":"The efficacy of intravenous morphine for acute migraine","volume":"20","author":"Friedman BW","year":"2013","journal-title":"Acad Emerg Med"},{"key":"e_1_2_12_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpain.2007.09.001"},{"key":"e_1_2_12_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annemergmed.2009.11.020"},{"key":"e_1_2_12_12_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1989.03420080094038"},{"key":"e_1_2_12_13_1","article-title":"Paracetamol (acetaminophen) with or without an antiemetic for acute migraine headaches in adults","volume":"4","author":"Derry S","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_2_12_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-1331.2008.02093.x"},{"key":"e_1_2_12_15_1","article-title":"Sumatriptan (oral route of administration) for acute migraine attacks in adults","volume":"2","author":"Derry CJ","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_2_12_16_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1468-2982.2001.00169.x"},{"key":"e_1_2_12_17_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1526-4610.2003.03043.x"},{"key":"e_1_2_12_18_1","doi-asserted-by":"publisher","DOI":"10.1212\/01.WNL.0000127304.91605.BA"},{"key":"e_1_2_12_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1526-4610.2005.05153.x"},{"key":"e_1_2_12_20_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1526-4610.2009.01346.x"},{"key":"e_1_2_12_21_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1526-4610.2008.01217.x"},{"key":"e_1_2_12_22_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.49.3.650"},{"key":"e_1_2_12_23_1","doi-asserted-by":"publisher","DOI":"10.1177\/0333102415620251"},{"key":"e_1_2_12_24_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1526-4610.1994.hed3409536.x"},{"key":"e_1_2_12_25_1","doi-asserted-by":"publisher","DOI":"10.1097\/WCO.0b013e3283378d5c"},{"key":"e_1_2_12_26_1","doi-asserted-by":"publisher","DOI":"10.1002\/ana.21077"},{"key":"e_1_2_12_27_1","doi-asserted-by":"publisher","DOI":"10.1152\/physrev.00034.2015"}],"container-title":["Headache: The Journal of Head and Face Pain"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/head.14185","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/head.14185","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/headachejournal.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/head.14185","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T13:30:54Z","timestamp":1762090254000},"score":1,"resource":{"primary":{"URL":"https:\/\/headachejournal.onlinelibrary.wiley.com\/doi\/10.1111\/head.14185"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,7]]},"references-count":26,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2021,9]]}},"alternative-id":["10.1111\/head.14185"],"URL":"https:\/\/doi.org\/10.1111\/head.14185","archive":["Portico"],"relation":{},"ISSN":["0017-8748","1526-4610"],"issn-type":[{"value":"0017-8748","type":"print"},{"value":"1526-4610","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,7]]},"assertion":[{"value":"2021-02-27","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-05-24","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-08-07","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}